with adalimumab becoming the most commonly used b/tsDMARD. Researchers performed a serial cross-sectional study using ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

Whereas 89.5% of new prescriptions for disease-modifying anti-rheumatic drugs (DMARDs) in 2000 were for old-line agents, by ...

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

Despite gastroenterologists' tendency to embrace biosimilar treatment options, the use of biosimilar adalimumab versus branded Humira remains comparable across specialties. AbbVie’s Humira ...

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...

The Adalimumab-aacf biosimilar, used to treat a variety of chronic inflammatory diseases including rheumatoid arthritis, psoriasis, and Crohn's disease, has undergone thorough evaluation of a ...

Comorbidities do not significantly impact treatment retention rates among patients with inflammatory RMDs who switch from originator to biosimilar adalimumab.

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.

Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA), according to ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...